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Background: Postpartum haemorrhage (PPH) remains a leading cause of maternal mortality worldwide. In Denmark
2% of parturients receive blood transfusion. During the course of bleeding fibrinogen (coagulation factor I) may be
depleted and fall to critically low levels, impairing haemostasis and thus worsening the ongoing bleeding. A plasma
level of fibrinogen below 2 g/L in the early phase of postpartum haemorrhage is associated with subsequent
development of severe haemorrhage. Use of fibrinogen concentrate allows high-dose substitution without the need
for blood type crossmatch. So far no publications of randomised controlled trials involving acutely bleeding patients in
the obstetrical setting have been published. This trial aims to investigate if early treatment with fibrinogen concentrate
reduces the need for blood transfusion in women suffering severe PPH.
Methods/Design: In this randomised placebo-controlled double-blind multicentre trial, parturients with primary PPH
are eligible following vaginal delivery in case of: manual removal of placenta (blood loss≥ 500 ml) or manual
exploration of the uterus after the birth of placenta (blood loss≥ 1000 ml). Caesarean sections are also eligible in case
of perioperative blood loss≥ 1000 ml. The exclusion criteria are known inherited haemostatic deficiencies, prepartum
treatment with antithrombotics, pre-pregnancy weight <45 kg or refusal to receive blood transfusion. Following
informed consent, patients are randomly allocated to either early treatment with 2 g fibrinogen concentrate or 100 ml
isotonic saline (placebo). Haemostatic monitoring with standard laboratory coagulation tests and thromboelastography
(TEG, functional fibrinogen and Rapid TEG) is performed during the initial 24 hours.
Primary outcome is the need for blood transfusion. To investigate a 33% reduction in the need for blood transfusion, a
total of 245 patients will be included. Four university-affiliated public tertiary care hospitals will include patients during
a two-year period. Adverse events including thrombosis are assessed in accordance with International Conference on
Harmonisation (ICH) good clinical practice (GCP).
Discussion: A widespread belief in the benefits of early fibrinogen substitution in cases of PPH has led to increased
off-label use. The FIB-PPH trial is investigator-initiated and aims to provide an evidence-based platform for the
recommendations of the early use of fibrinogen concentrate in PPH.
Trial registration: ClincialTrials.gov NCT01359878.
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Optimal haemostatic capacity during excessive bleeding
reduces mortality, blood loss and the need for transfusions
[1]. Pregnancy induces changes in coagulation towards a
more procoagulant state with mild thrombocytopenia,
increased procoagulant factors and diminished fibrinolysis
[2], ultimately serving as physiological protection against
postpartum bleeding. However, postpartum haemorrhage
(PPH) remains a leading cause of maternal mortality and
morbidity worldwide [3]. In Europe, 1.75 % of births are
complicated by severe PPH (blood loss> 1000 ml) [4]
with the risk of death in western countries at 1:100,000
births [5].
Hypofibrinogenaemia during postpartum haemorrhage
Acquired hypofibrinogenaemia develops early in relation
to fluid resuscitation, imbalanced transfusion of blood
components and bleeding [6]. This state of impaired
haemostasis also develops in relation to PPH [7-9]: a study
of 128 women suffering from PPH (blood loss of approxi-
mately 1000 ml) investigated by Charbit et al. [7] evalu-
ated the impact of coagulation on the course of bleeding.
The fibrinogen plasma level was identified as the only
early independent predictor of the subsequent develop-
ment of severe PPH. A fibrinogen level of below 2 g/L im-
plied a positive predictive value of 100% for the
development of severe PPH, whereas a level of below 4 g/
L implied a negative predictive value of 76%. ‘Severe PPH’
was defined as: ‘decrease of haemoglobin (Hb)> 4 g/dL
(>2.5 mmol/L), transfusion of at least four red blood cell
(RBC) units, haemostatic intervention (angiographic em-
bolisation, surgical arterial ligation or hysterectomy) or
death’.
Fibrinogen concentrate
Fibrinogen is essential in the development of a strong
and functional blood clot. It is produced in the liver and
the average plasma level is 2.0 to 4.5 g/L [10]. In relation
to pregnancy (especially the third trimester) the level of
fibrinogen rises to an average of 5 g/L [11]. Several stud-
ies addressing different clinical contexts of bleeding as-
sociate a low level of fibrinogen with increased
transfusion of blood products and amount of blood loss
during operation [8,10,12-18]. No optimal plasma level
of fibrinogen has so far been established [10,19-21]. Fi-
brinogen concentrate is a commercially available drug
produced from human plasma [22]. It undergoes viral
inactivation and does not require blood match or thaw-
ing prior to use. Traditionally, acquired hypofibrinogen-
aemia is treated with fresh frozen plasma (FFP) or
cryoprecipitate (Cryo) containing 2.5 g [10,19] and 15 g
per litre [16] respectively. Both blood products require
thawing and crossmatch before infusion. Thus, with FFP
a volume of 800 ml would be required to substitute 2 gof fibrinogen, corresponding to 133 ml of Cryo. However,
the use of FFP is associated with several transfusion-
related complications [23] rendering it a suboptimal treat-
ment for early prevention of fibrinogen deficiency. Cryo is
a pooled plasma product with one unit of Cryo exposing
the recipient to approximately four to six donors [24].
Only four randomised controlled trials (RCT) investi-
gating fibrinogen concentrate have been published so
far. One trial investigated the potential of fibrinogen
concentrate to reverse a colloid-induced impairment of
haemostasis (that is, coagulopathy) in elective surgical
patients undergoing radical cystectomy (n = 20) [25].
Two trials explored elective cardiac surgery (n = 20 [26],
n = 31 [27]). One trial included severely bleeding elective
surgical patients (n = 43) and investigated partial replace-
ment of FFP with fibrinogen concentrate [28]. None of
these studies were designed to evaluate a clinical out-
come, but indicated improved haemostasis [25,28] and a
potential ability to reduce the rate of blood transfusion
[25,27]. To our knowledge, no RCT has been published
addressing the effect of fibrinogen in acutely bleeding
patients or obstetric conditions. However, several publi-
cations have described experience from clinical use of fi-
brinogen concentrate [8,18,29-34] including a total of
144 cases of severe PPH with massive transfusion. In
these cases, treatment with fibrinogen concentrate seems
to be rapid and efficient in treating hypofibrinogenaemia
without any serious adverse events reported in the ob-
stetrical subpopulation. An incidence of 3.48 thrombotic
events per 105 treatments, using 4 g of fibrinogen con-
centrate in different clinical settings was reported in a
recent pharmacosurveillance for the period of 1986 to
2008 in 21 countries [35].
Need for a trial
The FIB-PPH trial will potentially provide evidence-
based knowledge on the feasibility of an early use of fi-
brinogen concentrate in PPH. Though the trial is not
powered to show a potential lifesaving effect, an effective
treatment reducing the need of red blood cell transfu-
sion could be beneficial. Allogenic blood transfusions
are associated with increased mortality and morbidity
[36,37]. Besides the potential risk of disease transmis-
sion, an immune modulation caused by the transfusion
of allogenic blood seems to increase the incidence of
infections, cancer relapse, transfusion-related lung injury
[19,21] and non-infectious serious hazards of transfusion
[23] and is associated with the phenomena of microchi-
merism [38,39]. Means to reduce allogenic blood trans-
fusions are currently being widely searched for and
examined.
Fibrinogen concentrate is increasingly being used in
the treatment of PPH. However, this remains off-label
use and is based on a low level of evidence. It is of
Wikkelsoe et al. Trials 2012, 13:110 Page 3 of 8
http://www.trialsjournal.com/content/13/1/110utmost importance to establish sound evidence before a
general implementation in the clinical setting. We need
to perform high-level RCTs before a more widespread
use of fibrinogen concentrate can be recommended.
Following the previously described work by Charbit
et al. [7] a high-quality trial addressing this matter is
needed in order to secure evidence-based treatment
and optimal use of economic resources.
Objective
The aim of this study is to evaluate whether initial treat-
ment with fibrinogen concentrate reduces the need for
allogenic blood transfusion in postpartum haemorrhage
(PPH). Other potential benefits and harms will be
assessed as secondary outcomes.
Methods and design
Overview
We are conducting a multicentre parallel placebo-
controlled randomised double-blind clinical trial with
1:1 allocation ratio. The trial is investigator initiated and
controlled and good clinical practice (GCP) monitored.
Inclusion criteria
Inclusion is possible if the following eligibility criteria
are met: 1) Informed consent from participant. 2)
Age ≥ 18 years. 3) PPH defined as bleeding from uterus
and/or the birth canal within 24 hours postpartum. 4)
Vaginal delivery and in need of anaesthesiological assist-
ance and either: a) estimated blood loss exceeding
500 ml and intended manual removal of placenta; or b)
estimated blood loss exceeding 1000 ml and intended
manual exploration of the uterus due to continuous
bleeding after the birth of placenta. 5) In case of birth by
caesarean section and estimated perioperative blood loss
exceeding 1000 ml (Figure 1).
Exclusion criteria
Participants fulfilling one or more of the following cri-
teria will be excluded: 1) Known inherited deficiencies of
coagulation. 2) Anti-thrombotic treatment prepartum
due to increased risk of thrombosis. 3) Pre-pregnancy
weight <45 kg. 4) Refusal to receive blood transfusion.
Randomisation and blinding
Allocation sequence is produced by a third party (phar-
macologists at Glostrup Pharmacy, Glostrup, Denmark)
using computer generation fixed block size with stratifi-
cation by centre. Allocation concealment is secured by
using sealed opaque numbered envelopes specially pre-
pared for this trial and this unique number is used as pa-
tient trial ID. Participants, outcome assessors, trials
investigators, statisticians and GCP trial monitors are
blinded, as well as care providers such as midwives,obstetricians, anaesthesiologists and anaesthetist nurses.
Anaesthetic personnel not involved in patient care ran-
domise the patient and dispense the trial medicine. Two
50 ml opaque syringes (yellow coloured) will be deliv-
ered to the operating theatre without revealing the allo-
cation. We register the success of blinding by asking the
responsible team/physician in the operating theatre fol-
lowing administration if he or she has any hint of the
allocated treatment and if yes, why. The patient is asked
during the follow-up period.Intervention
The participants are assigned to either 1) placebo (100 ml
isotonic saline) i.v. or 2) the intervention drug: 2 g of fi-
brinogen concentrate (Haemocomplettan/Riastap, CSL
Behring, Marburg, Germany) i.v. given via an infusion
pump in 20 minutes. We use a fixed dose for all patients
randomised to the intervention group without prior clin-
ical assessment of the fibrinogen level. This strategy is pri-
marily based on the clinical urgency since the treatment is
required to be administered as early as possible following
the inclusion. Dosage is based on a target level of 4 g/L [7]
and a mean fibrinogen level in women with 500 to
1000 ml blood loss of 3.4 g/L [9]. Thus, we calculated the
optimal dose using two different methods [10,25] in order
to increase the level approximately 0.6 g/L in the average
65.9 kg fertile woman in the Danish capital area (based on
data from the Danish National Board of Health) taking ei-
ther the increased plasma volume or weight gain during
pregnancy into account. An optimal dose of 2.2 to 2.7 g
was identified. However, considering the prothrombotic
state of pregnancy and postpartum period and the fact
that previous controlled clinical studies investigated
patients that were highly diluted with colloids [25] or
affected by the coagulopathies of extracorporeal circula-
tion [26,27], we pragmatically chose 2 g of fibrinogen con-
centrate as the intervention dose.Setting, location and follow-up
Parturients will be included during a two-year period at
the four largest hospitals in the Capital Region, Den-
mark. These four centres are university-affiliated public
tertiary care hospitals in the Copenhagen area each with
3500 to 7000 deliveries per year. Parturients are invited
to participate at the pre-anaesthetic evaluation and will
be hospitalised for at least 24 hours following inclusion.
Participants are contacted by phone six weeks after the
intervention, and they are able to contact the principal
investigator during the full trial period. Blood transfu-
sion and the use of tranexamic acid and other haemo-
static agents follow Danish standard recommendations
in all four centres and adherence to guidelines will be
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Figure 1 Trial flow. Patients scheduled for caesarean section or developing postpartum haemorrhage following vaginal delivery will be screened
for inclusion/exclusion and asked for consent to participate. Baseline blood samples are taken before intervention and patients are randomised to
either intervention (fibrinogen concentrate) or placebo (saline). Haemostatic monitoring (blood samples) is performed 15 minutes, 4 hours and 24
hours post-intervention together with a clinical status.
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The primary outcome is the need for transfusion with
allogenic blood products. Secondary outcomes will be de-
velopment of ‘severe PPH’ defined as: ‘decrease of haemo-
globin (Hb) of> 4 g/dl (2.5 mmol/L), transfusion of at
least four red blood cell (RBC) units, haemostatic inter-
vention (angiographic embolization, surgical arterial
ligation or hysterectomy) or death. We also evaluate esti-
mated blood loss, total amount of blood transfused, the
development of re-bleeding and Hb< 5.8 g/dL (3.6 mmol/
L)’. We will register potential side effects such as: fever,
headache, nausea, vomiting, allergic reactions, anaphylaxis
and thromboembolic complications (deep venous throm-
bosis, acute myocardial infarction and pulmonary embol-
ism) [40]. All suspected unexpected serious adversereactions will also be reported in accordance with the
International Conference on Harmonisation (ICH) GCP
and the Danish Medicines Agency guidelines.
Monitoring and data collection
Adherence to ICH GCP, including the Helsinki Declar-
ation, and trial protocol is being monitored by inde-
pendent monitors from the GCP unit at Copenhagen
University, and data are being collected on paper case
report forms. Transfusion data are assessed through
multiple data sources including the Capital Region
Blood Banks blood product registration system in
which all used blood products are registered together
with the recipient patients’ unique personal identifica-
tion (cpr) number. This ensures an almost complete
Table 1 List of baseline parameters/variables to be
assessed for baseline imbalance between treatment
groups in the final analysis
Baseline parameter/variable
The level of fibrinogen before intervention defined by
Clauss method (g/L)
Presence of hypofibrinogenaemia before intervention defined by
Clauss method (<2 g/L) and equivalent functional fibrinogen (TEG)
MA (< 14 mm or according to validation in this study).
Hypocoagulability prior to intervention measured with standard
TEG: R-time >8 min or alpha angle <55° or MA <50 mm or LY30 >8 %
Crystalloids used prior to intervention (ml)
Colloids used prior to intervention (ml)
The use of tranexamic acid prior to intervention (yes/no)
Mode of delivery Caesarean section
Vaginal delivery
Post vaginal procedure Intended manual removal of placenta
Manual exploration of the uterus
due to continuous bleeding after the
birth of placenta
Estimated blood loss before intervention (ml)*
Primary cause of PPH:
TRAUMA of the birth canal: paravaginal haematoma, cervical
laceration, vaginal laceration, perineal laceration, uterine rupture
Retained TISSUE: Retained placental tissue, Percrete or accrete placenta
Impaired THROMBOSIS: disseminated intravascular coagulation,
placental abruption, severe pre-eclampsia
Reduced TONE of uterus: uterine atony
Weight of parturient (kg) (because dose of fibrinogen= 2 g/BW kg)
Units of allogenic blood transfusion transfused prior to intervention
(numbers of units)
Bleeding duration (from start of bleeding to intervention) (min.)
Time from birth to intervention (min.)
Baseline haemoglobin (measured before intervention) (mmol/L or g/dL)
Method of anaesthesia: general versus regional anaesthesia
Adjusted analysis will be provided and results may guide further research in
this field.
Wikkelsoe et al. Trials 2012, 13:110 Page 5 of 8
http://www.trialsjournal.com/content/13/1/110follow-up excluding only patients withdrawing consent
to participate.
Haemostatic monitoring
Blood samples are drawn at inclusion before interven-
tion and at 15 minutes, 4 hours and 24 hours following
the termination of infusion. Blood transfusions, fluid
therapy, use of uterotonic and haemostatic drugs, and
amount of blood loss are assessed by anaesthetic
personnel before administration, 4 hours and 24 hours
after. We use haemostatic tests thrombelastography
(TEG, functional fibrinogen and Rapid TEG by Haemo-
scope Inc., Niles IL, USA) as well as standard tests such
as haemoglobin, factor level 2,7,10 (including inter-
national normalised ratio (INR)), activated partial
thromboplastin time (APTT), D-dimer, antithrombin III
and platelet count. Plasma fibrinogen level is measured
at all four time points but only the post-interventional
measurements will be available for clinical evaluation
and treatment aspects. Samples are collected and frozen
for later analysis.
Number of participants
Approximately 1% of parturients receive blood transfu-
sion [7,9,32,41-44] and 1.75% develop PPH (blood loss
>1000 ml) [4]. No studies conducted in the obstetric
target population were available during the design phase
of this trial, however, the two available RCTs found a re-
spectively 60% [25] and 20% but insignificant [26] risk
reduction in the need for allogenic blood transfusions.
Thus, we settled to investigate a risk reduction of 33%:
with α= 0.05 and power (β) = 80%, a number of 107
patients in each group are needed in order to evaluate a
33% reduction in the need for blood transfusion. With a
margin for missing data and dropouts of 15% - a total of
245 patients will be included.
Statistical methods and data analysis
The two groups will be compared using chi-square test
(binominal data) or Fischer’s exact test if numbers of
expected values are less than five (or an unconditional
exact test). Fibrinogen concentrate can potentially re-
verse the impaired haemostasis observed when using
colloids [25,45]. The potential effect of fibrinogen con-
centrate may rely on the pre-administered use of col-
loids, so sensitivity analysis and the influence of this will
be assessed together with other possible confounders
(baseline variables/parameters are presented in Table 1).
In accordance with ICH GCP recommendations on stat-
istical principles for clinical trials (E9) [46], we will
present adjusted and unadjusted analyses of the possible
effect. The baseline variables/parameters will be assessed
using multiple logistic regression models. The evaluation
of pre-specified subgroups demands more participantsthan planned in this trial, however, to explore and guide
further trials in this area we will perform two subgroups
analysis: one on mode of delivery (vaginal versus caesar-
ean section) and one on parturients with hypofibrino-
genaemia at intervention, thus guiding upcoming trials
in their selection of study population. All outcomes will
be reported as ‘intention-to-treat’ analysis including all
randomised patients fulfilling inclusion criteria and not
meeting exclusion criteria with a standing consent to
participate. Patients with the following major protocol
violations will not be included in a supplemental per-
protocol analysis: not receiving total dose and lack of
follow-up. The impact of blinding level will be explored
in a separate sensitivity analysis. Statistics will be per-
formed before the code of allocation is revealed. If the
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form complete case analysis. If more than 5% of missing
data is the case, we will present ‘worst-case’ and ‘best-
case’ analyses and if those are inconclusive, we will per-
form multiple imputations [47].
Consent and ethical considerations
Patients will provide informed consent during the pre-
anaesthetic assessment. An information brochure is given
beforehand to all pregnant women in the Capital Region by
midwives at a visit when 29 weeks pregnant, and again to
women requiring labour epidural. Before the caesarean sec-
tion or the post vaginal procedures patients are asked to
give their informed consent. Danish law does not provide
the option of including incapacitated patients using personal
or professional representatives in drug trials if some of the
eligible patients are able to give informed consent. The trial
is approved by the National Committee on Biomedical Re-
search Ethics 1002168/H-3-2010-004, the Danish Medicines
Agency (2612–4233/EudraCT 2009-017736-41) and the
Danish Data Protection Agency (2007-58-0015-00911). The
trial is registered at clincialtrials.gov (NCT01359878).
Discussion
This is the first randomised clinical trial investigating
the use of fibrinogen concentrate in acutely bleeding
patients in an obstetric setting. Furthermore, no previ-
ous report has evaluated the initial use of fibrinogen
concentrate during acute bleeding and its possible po-
tential effect to reduce the need for blood transfusion. In
this trial, we chose to give the same pre-emptive dose of
fibrinogen to all participant allocated to the intervention
group regardless of body weight and plasma level of fi-
brinogen in order to secure treatment being given as
early as possible. This implies the risk of giving a very
low dose to women with high body weight and thereby
potentially risking no treatment effect. On the other
hand, PPH may be caused by many other factors than
impaired haemostasis, such as atony or trauma of the
uterus or retained tissue [48]. Once these causes have
been treated bleeding usually stops. Thus by giving the
same dose to all without prior measurements of the fi-
brinogen level, we risk giving excess fibrinogen to some.
In this trial, close haemostatic monitoring with standard
laboratory tests and thrombelastography including func-
tional fibrinogen assay will reveal the haemostatic start-
ing point and monitor any hypercoagulability that might
occur.
Up to 1.9% of women giving birth in Denmark receive
at least one unit of RBC postpartum [49]. Acquired
hypofibrinogenaemia is a well-established cause of
bleeding due to impaired haemostasis, but in most coun-
tries fibrinogen concentrate is currently approved for
inherited hypofibrinogenaemia only. However, a generalperception of benefits and potentials of early pre-
emptive fibrinogen substitution has led to increased off-
label use [34].
The substitution of fibrinogen in patients with
acquired hypofibrinogenaemia is well-established as is
the essential role of fibrinogen in the achievement of
haemostasis in bleeding patients. However, the source of
fibrinogen (FFP, Cryo versus fibrinogen concentrate) is
still being debated together with the possible benefits
and risks of pre-emptive fibrinogen substitution
[10,24,50-54]: increasing the fibrinogen level to above
normal levels in obstetric patients with bleeding might
backfire, since these patients all ready have an increased
risk of thrombosis post-bleeding or post-surgery [54].
Several recent reviews address the topic, but the evi-
dence remains poor and inconclusive [10,51-53].
The FIB-PPH trial includes patients with postpartum
haemorrhage. Mortality is the ultimate outcome sum-
marising benefits and harms. However, a trial investigat-
ing this outcome in an obstetric setting would require
an extremely large sample size. An ongoing randomised
trial aiming at 15,000 participants worldwide investigates
the use of tranexamic acid in postpartum haemorrhage
with peripartum hysterectomy as outcome [55]. Trials of
this scale require good organisation and funding. There-
fore, with the sample size of 245 the FIB-PPH trial
should be considered a pilot study, but has the benefit of
being an independent investigator-initiated trial.
PPH is a potentially life-threatening acute condition
and, therefore, usually not suitable for trial inclusion
according to Danish laws and regulations. This could
lead to selection bias, as it may be difficult to include
the seriously affected women who may very well be the
subgroup benefiting most from this intervention. By
educating personnel and distributing information mater-
ial early in pregnancy, we hope to enable the inclusion
of the relevant population. Investigation of drugs consid-
ered for the treatment of acutely ill patients, such as
those with acute bleeding remains a challenge due to the
need for maintaining a balance between the patients’
rights for information and consent while at the same
time trying to provide evidence-based treatment strat-
egies. The use of personal or professional representatives
giving the initial consent is considered legal and prac-
tised with success in some countries [55].
A positive result, indicating a potential transfusion
sparring effect after births complicated by PPH, could
have great importance for developing countries. Fibrino-
gen concentrate can be stored for five years at room
temperature and no thawing or crossmatch is needed. A
negative result may indicate that early treatment with a
standard dose is potentially insufficient and further re-
search would be needed into thrombelastography-guided
treatment algorithms with a tight haemostasis control.
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The trial was initiated in June 2011 with a gradual start
at each centre. By November 2011, all four centres were
including participants. By June 25, 102 parturients had
been included.
We hope to increase the inclusion rate as well as the
proportion of patients with severe bleeding as the trial
will be fully implemented as part of the daily routine at
each hospital in the coming period.
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